Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Cancer Vaccine
Treatment CHP-MAGE-A4
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature MAGE-A3
Official Symbol MAGEA3
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental clinical trail
Description In the current clinical trial, antibody titers for three antigens of MAGE-A4, NY-ESO-1 and MAGE-A3 were significantly increased after vaccination compared with those before vaccination, in particular with MAGE-A4 in 8 of 12 patients (66.7%). Furthermore, antibody titers for NY-ESO-1 and MAGE-A3 also frequently increased regardless of the initial IHC posi-tivity of the resected specimen.
PMID 26888315
Title Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination